Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

117.36 -1.41 (-1.18%)
Streaming Delayed Price Updated: 12:56 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
ABBOTT LABORATORIES (NYSE:ABT) Technical Analysis observations.
Will ABBOTT LABORATORIES breakout? 
Via Chartmill
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Via The Motley Fool
ABBOTT LABORATORIES (NYSE:ABT) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Exploring ABBOTT LABORATORIES's Technical Signals and Breakout Potential. 
Via Chartmill
2 Dividend Kings to Buy for a Lifetime of Passive Income
Via The Motley Fool
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy. 
Via Talk Markets
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Via Benzinga
Analyst Ratings For Abbott Laboratories
Via Benzinga
Abbott Surges After Avoiding Another 'Eye-Popping' Verdict In Baby Formula Trial
Lawyers for the plaintiff had been arguing for a $6.2 billion verdict. 
Via Investor's Business Daily
P/E Ratio Insights for Abbott Laboratories
Via Benzinga
3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
These are income stocks you can buy and hold forever. 
Via The Motley Fool
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continues
Shares soared out of a buy zone after beating third-quarter forecasts and raising its outlook for 2024. 
Via Investor's Business Daily
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends. 
Via The Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
You'll also like these stocks for their track record of earnings growth. 
Via The Motley Fool
What You Missed On Wall Street This Past Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Is Abbott Laboratories Stock a Buy?
The healthcare stock is lagging the market this year. 
Via The Motley Fool
AbbVie’s Dividend Isn’t As Scary As It Looks
AbbVie currently pays shareholders a quarterly dividend of $1.55 per share, which gives the stock a 3.3% yield on the current price. 
Via Talk Markets
These Are The Top Health Stocks to Own for Buy-and-Hold Investing
The stocks on this list are the top three buy-and-hold stocks in healthcare, producing significant value for shareholders while leading their respective fields. 
Via MarketBeat
Exposures COVID-19
3 Dividend Growth Stocks You Can Buy and Hold Forever
These healthcare stocks have fantastic dividend track records. 
Via The Motley Fool
Beat the Nasdaq With This Cash-Gushing Dividend Stock
The company is performing well despite recently losing its biggest growth driver. 
Via The Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
These companies' longtime shareholders have generally been rewarded. 
Via The Motley Fool
MarketBeat Week in Review – 10/14 - 10/18
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election. 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Stock Market Rally At Highs; Taiwan Semi, ASML, Netflix In Focus: Weekly Review
The Dow Jones and S&P 500 hit highs as they extended weekly win streaks. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
These stocks could deliver big over the long term. 
Via The Motley Fool
Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
Abbott Laboratories reported Q3 sales of $10.64 billion, driven by 8.2% organic growth in medical devices. Adjusted EPS for 2024 projected at $4.64-$4.70, with expectations of double-digit growth... 
Via Benzinga
These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings
Via Benzinga
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
AbbVie Inc., which split from Abbott Laboratories remains more than a decade ago, is doing "very, very well," Jim Cramer says. 
Via Benzinga
Meta To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Why Abbott Laboratories Stock Was a Winner on Wednesday
Investors bumped its shares higher following a decent, if unspectacular, earnings report. 
Via The Motley Fool
Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
ABT earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Tech Stocks Stall, Small Caps Surge As Regional Banks Rally, Airlines Rocket: What's Driving Markets Wednesday?
Small-cap stocks outperformed large caps in Wednesday's session, with the Russell 2000 Index surging to test July 2024 highs on the back of expectations for interest rate cuts and a strong rally in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback